Hepatitis B Results Provide Boost To Dynavax's Stock Nov. 30, 2006 By Aaron Lorenzo Shares in Dynavax Technologies Corp. soared 32 percent Wednesday on positive Phase III data for its hepatitis B vaccine, Heplisav. (BioWorld Today)Read More